434 related articles for article (PubMed ID: 11436584)
1. [N-methyl glucamine antimoniate or Glucantime].
Rapp C; Simon F; Dordain ML
Med Trop (Mars); 2000; 60(4):342-3. PubMed ID: 11436584
[No Abstract] [Full Text] [Related]
2. [Acute pancreatitis during treatment with meglumine antimoniate (Glucantime)].
Barthet M; Brunet P; Bernard JC; Dussol B; Rodor F; Jouglard J; Berland Y; Sahel J
Gastroenterol Clin Biol; 1994; 18(1):90-2. PubMed ID: 8187998
[No Abstract] [Full Text] [Related]
3. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
[TBL] [Abstract][Full Text] [Related]
4. Meglumine antimoniate-induced pancreatitis.
Torrús D; Massa B; Boix V; Portilla J; Pérez-Mateo M
Am J Gastroenterol; 1996 Apr; 91(4):820-1. PubMed ID: 8677970
[No Abstract] [Full Text] [Related]
5. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
[TBL] [Abstract][Full Text] [Related]
6. Clinical follow-up examination after treatment of canine leishmaniasis.
Moritz A; Steuber S; Greiner M
Tokai J Exp Clin Med; 1998 Dec; 23(6):279-83. PubMed ID: 10622623
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.
Layegh P; Pezeshkpoor F; Soruri AH; Naviafar P; Moghiman T
Am J Trop Med Hyg; 2009 Feb; 80(2):172-5. PubMed ID: 19190206
[TBL] [Abstract][Full Text] [Related]
8. Drug hypersensitivity syndrome induced by meglumine antimoniate.
Jeddi F; Caumes E; Thellier M; Jauréguiberry S; Mazier D; Buffet PA
Am J Trop Med Hyg; 2009 Jun; 80(6):939-40. PubMed ID: 19478253
[TBL] [Abstract][Full Text] [Related]
9. [Glucantime reaction with fatal outcome following treatment of cutaneous leishmaniasis].
Hajlaoui K; Zeglaoui F; Ezzine N; Kastalli S; Elfekih N; Fazaa B; Loueslati MH; Kamoun MR
Ann Dermatol Venereol; 2008 Apr; 135(4):317-8. PubMed ID: 18420083
[No Abstract] [Full Text] [Related]
10. Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis.
Hantson P; Léonard ED; Crutzen-Fayt MC; Léonard A; Vandercam B; Delaere B; Mahieu P
Pharmacotherapy; 1996; 16(5):869-71. PubMed ID: 8888081
[TBL] [Abstract][Full Text] [Related]
11. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.
Esfandiarpour I; Farajzadeh S; Rahnama Z; Fathabadi EA; Heshmatkhah A
Int J Dermatol; 2012 Oct; 51(10):1221-5. PubMed ID: 22994669
[TBL] [Abstract][Full Text] [Related]
13. Pancreatitis associated with N-methyl-glucamine therapy in a dog with leishmaniasis.
Aste G; Di Tommaso M; Steiner JM; Williams DA; Boari A
Vet Res Commun; 2005 Aug; 29 Suppl 2():269-72. PubMed ID: 16244972
[No Abstract] [Full Text] [Related]
14. Efficacy of CO(2) laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate.
Shamsi Meymandi S; Zandi S; Aghaie H; Heshmatkhah A
J Eur Acad Dermatol Venereol; 2011 May; 25(5):587-91. PubMed ID: 20666876
[TBL] [Abstract][Full Text] [Related]
15. Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis.
de Lalla F; Pellizzer G; Gradoni L; Vespignani M; Franzetti M; Stecca C
Clin Infect Dis; 1993 May; 16(5):730-1. PubMed ID: 8507769
[No Abstract] [Full Text] [Related]
16. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
Layegh P; Yazdanpanah MJ; Vosugh EM; Pezeshkpoor F; Shakeri MT; Moghiman T
Am J Trop Med Hyg; 2007 Jul; 77(1):99-101. PubMed ID: 17620637
[TBL] [Abstract][Full Text] [Related]
17. Severe leucopenia during treatment of visceral leishmaniasis.
Hiçsönmez G; Jama H; Ozsoylu S
Trans R Soc Trop Med Hyg; 1988; 82(3):417. PubMed ID: 3232176
[No Abstract] [Full Text] [Related]
18. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
Moosavi Z; Nakhli A; Rassaii S
Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
[No Abstract] [Full Text] [Related]
19. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
Boumis E; Chinello P; Della Rocca C; Paglia MG; Proietti MF; Petrosillo N
Int J STD AIDS; 2006 May; 17(5):351-3. PubMed ID: 16643688
[TBL] [Abstract][Full Text] [Related]
20. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]